Hemlibra SC 105mg, manufactured by Chugai Pharmaceutical, contains emicizumab (genetically recombination) and is a bispecific antibody indicated for routine prophylaxis to prevent or reduce bleeding episodes in hemophilia A patients. It has a YJ code of 6343451A4024 and a standard of 105mg 0.7mL 1 bottle.
Hemlibra SC 105mg
Need more detailed information?
Contact TASAKI PHARMA for product sourcing, availability, or related support (English support available).